EF Hutton Maintains Buy on Anixa Biosciences, Maintains $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
EF Hutton analyst Jason Kolbert has reiterated a Buy rating for Anixa Biosciences (NASDAQ:ANIX) and maintained a price target of $10.
September 09, 2024 | 3:54 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EF Hutton analyst Jason Kolbert has reiterated a Buy rating for Anixa Biosciences and maintained a price target of $10, indicating confidence in the company's future performance.
The reaffirmation of a Buy rating and a $10 price target by EF Hutton suggests positive sentiment and confidence in Anixa Biosciences' future performance. This could lead to increased investor interest and potentially a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100